unmodified sknlp, with gene-modified sjnb-jf-il2 and sjnb-jf-ltn neuroblastoma cells
Vaccineexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01192555)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- unmodified sknlp, with gene-modified sjnb-jf-il2 and sjnb-jf-ltn neuroblastoma cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01192555 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2010 | Baylor University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2010 |
1 organizations
Page 1 / 1